Drug Use Investigation for PAXIL Tablet

Patients prescribed PAXIL

Patients with depression/depressed state or panic disorder prescribed PAXIL during study period

의약품: 파록세틴

CYP2D6에 의해 대사되는 약물의 병용 사용 유무

PAXIL은 약물 대사 효소 CYP2D6를 억제하며 이 CYP2D6 기능이 억제 효과에서 회복되는 데는 PAXIL 중단 후 약 1주일이 걸립니다. 이 회복기 동안 CYP2D6에 의해 대사되는 약물을 투여할 경우 주의가 필요하므로 이 약 치료를 중단한 환자에서 치료 중단 후 2주 이내에 CYP2D6에 의해 대사되는 약물의 사용 유무를 조사하기로 했다. , 뿐만 아니라 그것의 안전.

Incidence of adverse events in Japanese subjects treated with paroxetine tablet based on prescribing information under the conditions of general clinical practice

Presence/absence of concomitant use of products containing Saint John's Wort (Hypericum perforatum; "SJW", hereinafter)

Although the action mechanism for this is not clear, SJW has been reported to have the action of inhibiting reuptake of serotonin, noradrenaline and dopamine, and to exhibit an antidepressant effect. Since PAXIL also acts to inhibit serotonin reuptake, concomitant use of products containing SJW is thought to have an effect upon the serotonin reuptake inhibiting action of PAXIL, so it was decided to check for concomitant use of products containing SJW and investigate the safety of such concomitant use.